➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Johnson and Johnson
McKinsey
McKesson
Merck

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for BGJ398


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug BGJ398?

BGJ398 is an investigational drug.

There have been 20 clinical trials for BGJ398. The most recent clinical trial was a Phase 2 trial, which was initiated on December 31st 2018.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Cholangiocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Memorial Sloan Kettering Cancer Center.

There are one hundred and eighty US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for BGJ398
TitleSponsorPhase
Phase 1B Infigratinib +/-Tamoxifen or Fulvestrant&Palbociclib in Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-)/Fibroblast Growth Factor Receptors (FGFR) Altered BreastCancerBreast Cancer Research FoundationPhase 1
Phase 1B Infigratinib +/-Tamoxifen or Fulvestrant&Palbociclib in Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-)/Fibroblast Growth Factor Receptors (FGFR) Altered BreastCancerNational Cancer Institute (NCI)Phase 1
Phase 1B Infigratinib +/-Tamoxifen or Fulvestrant&Palbociclib in Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-)/Fibroblast Growth Factor Receptors (FGFR) Altered BreastCancerQED Therapeutics, Inc.Phase 1

See all BGJ398 clinical trials

Clinical Trial Summary for BGJ398

Top disease conditions for BGJ398
Top clinical trial sponsors for BGJ398

See all BGJ398 clinical trials

US Patents for BGJ398

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGJ398   Try Before You Buy Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein Astellas Pharma Inc. (Tokyo, JP)   Try Before You Buy
BGJ398   Try Before You Buy Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Try Before You Buy
BGJ398   Try Before You Buy Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Try Before You Buy
BGJ398   Try Before You Buy Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Try Before You Buy
BGJ398   Try Before You Buy Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGJ398

Drugname Country Document Number Estimated Expiration Related US Patent
BGJ398 Australia AU2013228389 2032-03-08   Try Before You Buy
BGJ398 Brazil BR112014021897 2032-03-08   Try Before You Buy
BGJ398 Canada CA2865388 2032-03-08   Try Before You Buy
BGJ398 China CN104379740 2032-03-08   Try Before You Buy
BGJ398 Eurasian Patent Organization EA029140 2032-03-08   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
Johnson and Johnson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.